Royalty Report: Drugs, cardiac, Disease – Collection: 28684


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 5


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5

Primary Industries

  • Drugs
  • cardiac
  • Disease
  • Therapeutic
  • Pharmaceuticals
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 28684

License Grant
The Licensor is developing a cell therapy for the treatment of cardiovascular disease.

The Merger Agreement requires the Licensee to pay certain earn out payments following the first commercial sale of AMR-001 for the benefit of the former stockholders of the Licensor.

License Property
The Licensor's lead compound, AMR-001, now represents the Licensee's most clinically advanced therapeutic and has commenced enrollment for a Phase 2 trial to investigate AMR-001’s efficacy in preserving heart function after a heart attack.
Field of Use
The Licensee also expects to begin a Phase 1 clinical trial by 2013 to investigate AMR-001’s utility in arresting the progression of congestive heart failure and the associated comorbidities of that disease.

IPSCIO Record ID: 359108

License Grant
Canadian Licensor granted Licensee the sole, exclusive, irrevocable license to patented nanotechnologies for use with any drugs including cannabinoids,  to develop and optimize a proprietary nanoformulation of pharmaceutical cannabidiol, designed to avoid first-pass metabolism and improve bioavailability, for the treatment of heart failure.
License Property
Nanotechnologies are designed to improve solubilization, pharmacokinetics, and drug targeting of lipophilic drugs. Nanotechnologies is the use of matter on an atomic, molecular, and supramolecular scale for industrial purposes.

Cannabidiol is a non-psychoactive molecule with broad therapeutic potential in the treatment of chronic inflammatory disease including heart failure.

Field of Use
The license to patented nanotechnologies is for use with any drugs or classes of drugs currently used or developed in the future to diagnose or treat heart failure and/or any cardiovascular disease and/or cardiopulmonary disease and/or cardiac arrhythmias.

Field of use to treat cardiovascular disease, cardiopulmonary disease, and cardiac arrhythmias.

IPSCIO Record ID: 27836

License Grant
Mydicar is a gene therapy currently being developed by the Licensee to treat advanced heart failure utilizing targeted proprietary AAV-1 technology. Presently, without a transplant the vast majority of heart failure patients die within 5-7 years. May 30th, 2010, Licensee presented at the European Society of Cardiology in Berlin 6-month data from CUPID, its’ Phase II trial of Mydicar. Based on our due diligence at the ESCO conference and our confidence that the CUPID trial met and exceeded its’ endpoints, we believe it is very likely that the Licensee will initiate a Phase III trial for Mydicar within the next 6-9 months.

IPSCIO Record ID: 28000

License Grant
The Licensor granted an exclusive option to license its product candidate, TRV027. If Licensee exercises this option, the license agreement will become effective and Licensee will have an exclusive worldwide license to develop and commercialize TRV027 and specified related compounds.  The Licensor is about to conduct a Phase 2b trial of TRV027 in acute heart failure.
License Property
TRV027 is an intravenous drug for the treatment of acute heart failure (AHF) in combination with standard diuretic therapy, and is currently being investigated in a Phase 2 clinical trial.

IPSCIO Record ID: 240585

License Grant
The Parties have agreed to collaborate together in order to develop, improve, and commercialize therapeutics for the treatment of cardiovascular disease based upon Licensors proprietary technology.

Licensor, an individual, grants an exclusive, worldwide right and license during the term of this Agreement under all of Licensors rights in the Patent Rights and Technical Information to make, have made, use, have used, sell, have sold, and import, Collaboration Products.

License Property
Licensor has developed certain proprietary technology related to the combination of hydralazine and isosorbide dinitrate for the treatment of cardiovascular disease.

The patent is for Method of Reducing Mortality Associated with Congestive Heart Failure Using 1-Hydralazine and Isosorbide Dinitrate.

Field of Use
The field shall mean the combination of hydralazine and isosorbide dinitrate, with or without one or more additional active ingredients for the treatment of cardiovascular diseases.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.